Nice | Rivaroxaban for treating PE and preventing recurrent embolism

2nd August 2013 by Louise Hudman

Another guideline about Rivaroxaban. Guidance was published in 2012 advising that Rivaroxaban could be used in the treatment of DVT. At that point, there was no guidance about its use in PEs. Since then a study has shown that it is as effective as Warfarin in the treatment of PE. Therefore this new guideline advises that Rivaroxaban can be used in the treatment of PE and for the prevention of recurrent PE and DVT.

Its main advantage is that it does not need monitoring. Its main disadvantage is that its effects are not easily reversible. It is also expensive.

 

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"I am all set up and running on LocumDeck. I'm very impressed by how efficient and smooth it seems."

Dr Paula Zukowski

Dr Paula Zukowski

See the full list of features within our NASGP membership plans

Membership